Compare Firy Inc. (FIRY) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Firy Inc. vs Organon & Co. Common Stock — how do they compare? Firy Inc. trades at $11.27 (market cap $206.28M), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Organon & Co. Common Stock is far larger — about 17.5× Firy Inc.'s market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Firy Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Firy Inc. for 13 Days and Organon & Co. Common Stock for 0 Days on average.
| FIRY | OGN | |
|---|---|---|
Market Cap | $206.28M | $3.62B |
Volume | 112,784 | 2,892,999 |
Sector | Technology | Health |
52-Week High | $13.10 | $13.81 |
52-Week Low | $2.28 | $5.70 |
Typical Hold Time | 13 Days | 0 Days |
Enterprise Value | $174.88M | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIRY (formerly Skillz Inc.) trades at $11.17, down 9.85% in the last session. The technical outlook is bullish based on moving averages, though oscillators are neutral. Fundamentally, the company shows persistent losses with a net income margin of -60.23% despite an 87.76% gross margin. Recent developments include a $719 million legal victory and board additions, but cash burn remains a concern with negative operating cash flow of $68.93 million in 2025.
The outlook is cautious. While the legal win and strategic shifts offer potential upside, sustained losses and negative cash flow pose significant risks. Analyst sentiment is mixed with 60% hold ratings. Key catalysts include the collection of the legal judgment and improved operational efficiency, but investors face substantial execution and liquidity risks.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
